Paradigm Biocapital Advisors LP 13F: Quarter-over-Quarter Portfolio Changes
Paradigm Biocapital Advisors LP reported a disclosed portfolio value of approximately $5.3 billion in its latest SEC Form 13F-HR filing for Q2 2026, up 9.1% quarter on quarter. Over the quarter, the fund initiated 7 new positions, bought more shares in 12 holdings, trimmed 7 holdings, and exited 14 positions.
Paradigm Biocapital Advisors LP's top buy was a new stake in Alnylam Pharmaceuticals INC (ALNY) , equal to 2.7% of the disclosed portfolio. Its top sell was Arcellx INC (ACLX) . The fund exited the position completely after it had accounted for 13.5% of the previous portfolio.
New PositionsQ2 2026
Securities disclosed for the first time in Q2 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Portfolio Weight | History |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | ALNY | 2.7% | Holders → |
| MBX BIOSCIENCES INC | MBX | 2.6% | Holders → |
| JADE BIOSCIENCES INC | JBIO | 1.2% | Holders → |
| ACHIEVE LIFE SCIENCE INC | ACHV | 0.6% | Holders → |
| MAPLIGHT THERAPEUTICS INC | MPLT | 0.5% | Holders → |
| KARDIGAN INC | KARD | 0.4% | Holders → |
| EDITAS MEDICINE INC | EDIT | 0.3% | Holders → |
Top BuysQ2 2026
Showing the top 10 buys among 12 existing positions where the fund bought more shares in Q2 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| ASSEMBLY BIOSCIENCES INC | ASMB | +0.4% | +133.6% | Holders → |
| VIRIDIAN THERAPEUTICS INC | VRDN | +1.1% | +113.5% | Holders → |
| SPYRE THERAPEUTICS INC | SYRE | +4.4% | +96.2% | History → |
| GENMAB A/S | GMAB | +2.4% | +64.8% | History → |
| TANGO THERAPEUTICS INC | TNGX | +2.0% | +58.6% | History → |
| EDGEWISE THERAPEUTICS INC | EWTX | +3.0% | +38.7% | History → |
| APOGEE THERAPEUTICS INC | APGE | +1.6% | +16.9% | History → |
| NUVALENT INC | NUVL | +2.6% | +11.3% | History → |
| BELITE BIO INC | BLTE | +-0.1% | +10.6% | History → |
| TARSUS PHARMACEUTICALS INC | TARS | +-0.4% | +8.3% | Holders → |
Top SellsQ2 2026
The fund's top sells among positions it retained in Q2 2026. Ranked by portfolio-weight impact. Full exits are listed separately.
| Company | Ticker | Portfolio Weight Change | Shares Sold | History |
|---|---|---|---|---|
| VAXCYTE INC | PCVX | -3.4% | 55.6% | Holders → |
| LEXEO THERAPEUTICS INC | LXEO | -0.4% | 32.5% | Holders → |
| TYRA BIOSCIENCES INC | TYRA | -0.5% | 11.0% | Holders → |
| ERASCA INC | ERAS | -0.2% | 8.1% | History → |
| EYEPOINT INC | EYPT | -0.1% | 8.0% | Holders → |
| ORUKA THERAPEUTICS INC | ORKA | 1.5% | 7.6% | History → |
| REVOLUTION MEDICINES INC | RVMD | 9.1% | 4.4% | History → |
Full ExitsQ2 2026
Positions present in the prior 13F-HR filing that no longer appear in Q2 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| ARCELLX INC | ACLX | 13.5% |
| CENTESSA PHARMACEUTICALS PLC | CNTA | 2.9% |
| TERNS PHARMACEUTICALS INC | TERN | 2.4% |
| CYTOKINETICS INC | CYTK | 2.0% |
| ABIVAX SA | ABVX | 1.8% |
| MAZE THERAPEUTICS INC | MAZE | 1.7% |
| SCHOLAR ROCK HLDG CORP | SRRK | 1.2% |
| MIRUM PHARMACEUTICALS INC | MIRM | 1.2% |
| VERADERMICS INC | MANE | 0.7% |
| UROGEN PHARMA LTD | URGN | 0.6% |
| STRUCTURE THERAPEUTICS INC | GPCR | 0.5% |
| ORIC PHARMACEUTICALS INC | ORIC | 0.4% |
| BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | 0.2% |
| KALARIS THERAPEUTICS INC | KLRS | 0.1% |
Net Portfolio Value ChangeQ2 2026
- $4.9BPrior quarter
- $5.3BCurrent quarter
- +$0.4BNet delta
- +9.1%% change
Methodology & FAQ
How Paradigm Biocapital Advisors LP Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for Paradigm Biocapital Advisors LP: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description, including how confidential treatment filings are handled, is documented in the Methodology.
What stocks did Paradigm Biocapital Advisors LP buy in Q2 2026?
In Q2 2026, Paradigm Biocapital Advisors LP initiated 7 new positions (ALNYLAM PHARMACEUTICALS INC (ALNY), MBX BIOSCIENCES INC (MBX), JADE BIOSCIENCES INC (JBIO), ACHIEVE LIFE SCIENCE INC (ACHV), MAPLIGHT THERAPEUTICS INC (MPLT), KARDIGAN INC (KARD), EDITAS MEDICINE INC (EDIT)); bought more shares of ASSEMBLY BIOSCIENCES INC (ASMB), VIRIDIAN THERAPEUTICS INC (VRDN), SPYRE THERAPEUTICS INC (SYRE), GENMAB A/S (GMAB), TANGO THERAPEUTICS INC (TNGX) (the largest 5 of 12 adds).
What stocks did Paradigm Biocapital Advisors LP sell in Q2 2026?
In Q2 2026, Paradigm Biocapital Advisors LP fully sold 14 positions (ARCELLX INC (ACLX), CENTESSA PHARMACEUTICALS PLC (CNTA), TERNS PHARMACEUTICALS INC (TERN), CYTOKINETICS INC (CYTK), ABIVAX SA (ABVX), MAZE THERAPEUTICS INC (MAZE), SCHOLAR ROCK HLDG CORP (SRRK), MIRUM PHARMACEUTICALS INC (MIRM), VERADERMICS INC (MANE), UROGEN PHARMA LTD (URGN), STRUCTURE THERAPEUTICS INC (GPCR), ORIC PHARMACEUTICALS INC (ORIC), BRIDGEBIO ONCOLOGY THERAPEUT (BBOT), KALARIS THERAPEUTICS INC (KLRS)); reduced holdings in VAXCYTE INC (PCVX), LEXEO THERAPEUTICS INC (LXEO), TYRA BIOSCIENCES INC (TYRA), ERASCA INC (ERAS), EYEPOINT INC (EYPT) (the largest 5 of 7 reductions).
Which positions did Paradigm Biocapital Advisors LP initiate in Q2 2026?
Paradigm Biocapital Advisors LP established 7 new positions in Q2 2026: ALNYLAM PHARMACEUTICALS INC (ALNY, 2.7%), MBX BIOSCIENCES INC (MBX, 2.6%), JADE BIOSCIENCES INC (JBIO, 1.2%), ACHIEVE LIFE SCIENCE INC (ACHV, 0.6%), MAPLIGHT THERAPEUTICS INC (MPLT, 0.5%), KARDIGAN INC (KARD, 0.4%), EDITAS MEDICINE INC (EDIT, 0.3%).
Which existing positions saw the largest allocation increases for Paradigm Biocapital Advisors LP in Q2 2026?
Of 12 existing positions with share-count increases in Q2 2026, the largest were: ASSEMBLY BIOSCIENCES INC (ASMB, +0.4% weight, +133.6% shares), VIRIDIAN THERAPEUTICS INC (VRDN, +1.1% weight, +113.5% shares), SPYRE THERAPEUTICS INC (SYRE, +4.4% weight, +96.2% shares), GENMAB A/S (GMAB, +2.4% weight, +64.8% shares), TANGO THERAPEUTICS INC (TNGX, +2.0% weight, +58.6% shares), EDGEWISE THERAPEUTICS INC (EWTX, +3.0% weight, +38.7% shares), APOGEE THERAPEUTICS INC (APGE, +1.6% weight, +16.9% shares), NUVALENT INC (NUVL, +2.6% weight, +11.3% shares), BELITE BIO INC (BLTE, +-0.1% weight, +10.6% shares), TARSUS PHARMACEUTICALS INC (TARS, +-0.4% weight, +8.3% shares).
Which positions did Paradigm Biocapital Advisors LP fully exit in Q2 2026?
Paradigm Biocapital Advisors LP fully exited 14 positions in Q2 2026: ARCELLX INC (ACLX, last-reported weight 13.5%), CENTESSA PHARMACEUTICALS PLC (CNTA, last-reported weight 2.9%), TERNS PHARMACEUTICALS INC (TERN, last-reported weight 2.4%), CYTOKINETICS INC (CYTK, last-reported weight 2.0%), ABIVAX SA (ABVX, last-reported weight 1.8%), MAZE THERAPEUTICS INC (MAZE, last-reported weight 1.7%), SCHOLAR ROCK HLDG CORP (SRRK, last-reported weight 1.2%), MIRUM PHARMACEUTICALS INC (MIRM, last-reported weight 1.2%), VERADERMICS INC (MANE, last-reported weight 0.7%), UROGEN PHARMA LTD (URGN, last-reported weight 0.6%), STRUCTURE THERAPEUTICS INC (GPCR, last-reported weight 0.5%), ORIC PHARMACEUTICALS INC (ORIC, last-reported weight 0.4%), BRIDGEBIO ONCOLOGY THERAPEUT (BBOT, last-reported weight 0.2%), KALARIS THERAPEUTICS INC (KLRS, last-reported weight 0.1%).
Which existing positions saw the largest allocation reductions for Paradigm Biocapital Advisors LP in Q2 2026?
Of 7 existing positions with share-count reductions in Q2 2026, the largest were: VAXCYTE INC (PCVX, -3.4% weight, -55.6% shares), LEXEO THERAPEUTICS INC (LXEO, -0.4% weight, -32.5% shares), TYRA BIOSCIENCES INC (TYRA, -0.5% weight, -11.0% shares), ERASCA INC (ERAS, -0.2% weight, -8.1% shares), EYEPOINT INC (EYPT, -0.1% weight, -8.0% shares), ORUKA THERAPEUTICS INC (ORKA, 1.5% weight, -7.6% shares), REVOLUTION MEDICINES INC (RVMD, 9.1% weight, -4.4% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.